GHRP-6 and Ipamorelin are both growth hormone-releasing peptides (GHRPs) that stimulate the body's natural production of growth hormone. Our corpus suggests their primary use case is as growth hormone secretagogues, with evidence indicating they can significantly boost bone mineral content, at least in preclinical animal models. Both peptides have also been investigated in the context of anti-doping efforts due to their potential for misuse in sports. Ipamorelin, in particular, has shown promise in accelerating gastrointestinal recovery after surgery, potentially reducing postoperative ileus and shortening hospital stays in human trials.
| GHRP-6 | Ipamorelin | |
|---|---|---|
| Drug class | ghrelin mimetic | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 105 | 45 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | preclinical animal · 67 other · 14 in vitro · 18 rct · 1 review · 5 | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 |
| Studies with explicit sample size | 1 | 3 |
| Head-to-head studies in corpus | 11 | |
Studies in our corpus that mention both GHRP-6 and Ipamorelin — the gold-standard direct comparison evidence.
This study highlights a critical paradox in diabetes: GH hypersecretion coexisting with peripheral GH receptor resistance. This finding suggests that the body attempts to compensate for impaired GH signaling by increasing GH production, but target tissues r…
This advanced analytical method provides a crucial tool for anti-doping agencies to combat the illicit use of GHRPs in both equine and human sports. By enabling reliable and high-throughput detection, it helps ensure fair competition and protects athlete he…
This study marks a significant advancement by identifying Ipamorelin as the first truly selective growth hormone secretagogue, offering a cleaner pharmacological profile. The absence of significant prolactin or cortisol elevation suggests a reduced risk of …
This research provides a crucial mechanistic insight into how GHRPs stimulate growth hormone release, suggesting a significant interaction with the body's endogenous ghrelin system. Understanding this pathway could lead to the development of more effective …
This study reveals a critical GH-independent mechanism by which GHSs can increase body fat, potentially driven by increased feeding and altered metabolic signaling. This finding is highly significant for understanding the full physiological impact and poten…
This foundational research is profoundly significant as it underscores the promising potential of GH secretagogues as a novel therapeutic strategy for managing and preventing conditions characterized by bone loss, such as osteoporosis. By leveraging the bod…
This research significantly enhances anti-doping capabilities by providing specific, long-lasting biomarkers for GHRPs administered nasally. The identification of these metabolites means that athletes misusing these substances can be detected for a much lon…
This study provides crucial evidence of the ongoing misuse of GHRP-2 and GHRP-6 in sports and validates a robust analytical method for their detection. The ability to accurately identify these peptides in athlete urine significantly strengthens anti-doping …
Improved and more sensitive detection methods are paramount for maintaining the integrity and fairness of competitive sports. By identifying novel metabolites and optimizing analytical protocols, this research significantly enhances the ability of anti-dopi…
This study provides a highly sensitive and robust analytical tool that significantly enhances the capabilities of anti-doping laboratories to detect GHRP abuse. By simultaneously identifying both parent GHRPs and their metabolites, the method extends the de…
No direct head-to-head trials in our corpus. Indirect comparison only. While both GHRP-6 and Ipamorelin function as growth hormone secretagogues, Ipamorelin is highlighted in preclinical studies as a more selective secretagogue, potentially offering a cleaner pharmacological profile with a reduced risk of elevating prolactin or cortisol levels compared to non-selective GHSs. GHRP-6's mechanism may involve interaction with the ghrelin system in the stomach, and some preclinical studies suggest GHSs can increase body fat independently of growth hormone, potentially through increased feeding. In terms of evidence tier, our corpus includes human randomized controlled trials for Ipamorelin exploring its effects on growth hormone release and bowel recovery after surgery, indicating a more advanced stage of clinical investigation for these specific applications compared to GHRP-6, for which human RCTs in our corpus are not detailed for specific outcomes beyond anti-doping detection.
Looking for vendor-level purity, endotoxin, and HPLC data on GHRP-6 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.